| pubmed-article:18294842 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C0034251 | lld:lifeskim |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C0812230 | lld:lifeskim |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C0812228 | lld:lifeskim |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:18294842 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:18294842 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18294842 | pubmed:dateCreated | 2008-3-17 | lld:pubmed |
| pubmed-article:18294842 | pubmed:abstractText | This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic profile of an optimized inhibitor that has low clearance and long half-life in dogs. | lld:pubmed |
| pubmed-article:18294842 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18294842 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18294842 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18294842 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18294842 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:HartmanGeorge... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:RobinsonRonal... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:HuberHans EHE | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:BilodeauMark... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:WuZhicaiZ | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:HartnettJohn... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:JonesRaymond... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:BarnettStanle... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:Defeo-JonesDe... | lld:pubmed |
| pubmed-article:18294842 | pubmed:author | pubmed-author:KralAstrid... | lld:pubmed |
| pubmed-article:18294842 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18294842 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18294842 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18294842 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18294842 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18294842 | pubmed:pagination | 2194-7 | lld:pubmed |
| pubmed-article:18294842 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:meshHeading | pubmed-meshheading:18294842... | lld:pubmed |
| pubmed-article:18294842 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18294842 | pubmed:articleTitle | Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. | lld:pubmed |
| pubmed-article:18294842 | pubmed:affiliation | Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486, USA. john_hartnett@merck.com | lld:pubmed |
| pubmed-article:18294842 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18294842 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18294842 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18294842 | lld:pubmed |
